News for hackers. Stuff that matters.
Re:C diff spores resist bleach and remain viable on surgical... by zer00eyz on Thursday November 23, 2023 @03:47PM (#38397355)
An efficient market is characterized by a perfect, complete, costless, and instant transmission of information...

You have conflated your incentive (a cure) with people who make and sell treatments (maximize profits).

As long as there are Pharma companies, there is incentive to make slightly better treatments. That is same effect lower production cost, or same cost and better effect.

It kind of sad that treatements have gone from prescription to subscription.

Re:C diff spores resist bleach and remain viable on surgical... by shoubidouwah on Thursday November 23, 2023 @04:04PM (#38397526)
Just wanted to add as an additional wrinkle in the simple ecomnomic explanations : a lot of the "discovering drugs" part -still necessary before you can actually sell drugs, afaik-, hinges very much on having really good researchers work for you. And these researchers do care about curing diseases: I do not have one colleague that does not dream of being a new Salk. The market needs thus to correct for it: it tends to be more efficient / worth it to be ethical, because it is a prerequisite for top talent hiring in this space.

This is of course complicated further by the sheer pigheadedness of CEOs with a career half life of 3 years who come in, _revolutionize_ something by destroying it and antagonizing the workers, bloat HR a bit more and drive sales through something illegal; and finally move on, tallying that one a success.

Re:C diff spores resist bleach and remain viable on surgical... by anonymouskimmer on Thursday November 23, 2023 @07:45PM (#38399544)
I completely agree with you, but as you imply CEO-driven decisions can intervene.

https://www.propublica.org/article/how-big-pharma-company-st...

Two vaccine candidates use the same adjuvant. One demonstrates high efficacy at curing a disease killing over a million people per year in poorer countries, one demonstrates high efficacy in preventing shingles. Guess which one was prioritized for the adjuvant.

Re:C diff spores resist bleach and remain viable on surgical... by gumby on Friday November 24, 2023 @12:06AM (#38400795)
I can believe everything about that article except the explanation that the adjuvant itself was somehow the bottleneck. GSK simply didn’t see a way to make money from the TB case; the adjuvant seems tangential despite the way it was presented in the article. It reads as if the author just learned the word and didn’t understand its actual significance. The adjuvant function is useful in other contexts but vaccines!

Also shingles can be a serious disease. Doesn’t change the calculus of prevalence, but no need to be quite so dismissive.

Re:C diff spores resist bleach and remain viable on surgical... by anonymouskimmer on Friday November 24, 2023 @12:13AM (#38400830)
It could be. It depends on the source and cost per dose of the adjuvant. Adjuvants from natural products can be supply limited and also costly to produce.

Regardless, it makes you wonder why they went forward with that particular adjuvant for the TB trial in the first case.

I'm not dismissing shingles, just triaging it relative to the seriousness of TB.

Re:C diff spores resist bleach and remain viable on surgical... by gumby on Friday November 24, 2023 @12:54AM (#38400988)
> Regardless, it makes you wonder why they went forward with that particular adjuvant for the TB trial in the first case.

Well sometimes you select an excipient or adjuvant because some other one you might have chosen has some interaction with your API (active pharmaceutical ingredient -- the thing you're actually trying to deliver). More often though they are pretty arbitrary: the program lead or someone on the team had used that compund before and knew how to handle it or already had all the literature needed for a regulatory submission (had an older submission) or perhaps the division you're submitting to is already quite familiar with that one so you use it.

And of course once you're approved for and done an initial trial (phase 1) with one formulation you don't want to go back and redo all the safety studies, especially for something that isn't the API itself, if you don't have to.

Note, I have not worked in vaccines, only in anti-infectives, so their can always be cultural and technical differences that I'm not aware of! Consider this the equivalent of "experienced Lisp, C++ and assembly programmer reads article written by a layperson about a problem with a Java program, and is dubious about the layperson's diagnosis".

Re:C diff spores resist bleach and remain viable on surgical... by anonymouskimmer on Friday November 24, 2023 @01:22AM (#38401109)
:) I'm a synthetic biologist, but don't work with eukaryotes outside of knowing some basics about expression cassettes, so sure.

I don't know to what extent the ProPublica writer was informed by their sources, but they're typically pretty good journalists. Still, I get your point.

Re:C diff spores resist bleach and remain viable on surgical... by Grimblewald on Thursday November 23, 2023 @03:52PM (#38397396)
Everything is going the way of subscriptions. Ill probably be in subscription housing the rest of my life unless there is a crash in the property market.
Re:C diff spores resist bleach and remain viable on surgical... by selcuka on Thursday November 23, 2023 @08:22PM (#38399784)
Housing has always been a subscription, you can't really technically own your house (try not paying your land tax).